Frontlight ResearchEarly access
Metastatic breast cancer trials in Germany
47 of 52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 3Taking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Dresden, Munich
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Amberg, Berlin, Bottrop, Duesseldorf, Erfurt, Erlangen, Freiburg Im Breisgau, Muenster, Munich, Saarbruecken, Ulm
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - Phase 3Taking peopleBGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
- Where
- Berlin, Bochum, Bottrop, Cologne, Dresden, Duesseldorf, Essen, Esslingen am Neckar, Frankfurt/Main, Hamburg, Hanover, Homburg, Hösbach, Kiel, Koblenz, Leipzig, Lübeck, Muenster, Munich, Ravensburg, Velbert, Westerstede
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00 - Phase 1/2Taking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Erlangen, Essen
- Age
- 18 years and over
- People
- 1,132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - Phase 3Taking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Aachen, Aschaffenburg, Bottrop, Dresden, Eggenfelden, Erlangen, Freiburg im Breisgau, Freiburg Im Breisgau, Krefeld, Mannheim, Munich
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - Phase 2/3Taking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Dessau, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen, München, Paderborn, Witten, Wuppertal
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Cologne, Dresden, Essen, Halle Saale, Hamburg, Hanover, Heidelberg, Koblenz, Langen (Hessen), Muenster, Potsdam, Regensburg, Saarbruecken, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - Phase 3Not yet taking people in GermanyA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Friedrichshafen, Göttingen, Hamburg, Homburg, Leipzig, Ludwigsburg, Mainz, München, Potsdam, Suhl, Wiesbaden, Witten, Wuppertal
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - Phase 3Taking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Chemnitz, Detmold, Dortmund, Homburg, Trier, Ulm
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - Phase 2Taking peopleA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Where
- Aachen, Dessau-Rosslau, Duesseldorf, Essen, Heidelberg, Penzberg, Tuebingen
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00 - Phase 3Taking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- Berlin, Bottrop, Cologne, Dresden, Essen, Muenster, Munich, Ulm
- Age
- 18 years and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - Phase 3Taking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Aachen, Augsburg, Berlin, Dessau-Rosslau, Duesseldorf, Erlangen, Goettingen, Hamburg, Hanover, Heidelberg, Kiel, Leipzig, Ludwigsburg, Muenster, Munich
- Age
- 18 years and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - Phase 3Active, not recruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Aachen, Essen, Freiburg Im Breisgau, Georgsmarienhuette, Goettingen, Hamburg, Hanover, Heidelberg, Moenchengladbach, Munich, Paderborn
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1Taking peopleA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Cologne, Essen
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - Phase 1Not yet taking people in GermanyA clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Where
- Frankfurt Am Main, Ulm
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522707-26-00 - Phase 2Not yet taking people in GermanyEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Leipzig
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Augsburg, Berlin, Duesseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Magdeburg, Ravensburg, Ulm
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - Phase 3Not yet taking people in GermanyA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Where
- Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier, Velbert
- Age
- 18 years to 130 years
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07647328 - Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Berlin, Düsseldorf, Erlangen, Essen, Georgsmarienhütte, Gera, München, Potsdam, Saarbrücken
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - Phase 1/2Taking peopleTo compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
- Where
- Dresden, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Tuebingen
- Age
- 18 years and over
- People
- 73 worldwide
- Run by
- Genentech Inc.
See details and how to join2025-521128-31-00 - Phase 3Not yet taking people in GermanyPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Duesseldorf, Mainz, Saarbruecken, Wuppertal
- Age
- 18 years and over
- People
- 1,180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - Phase 2Not yet taking people in GermanyA TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
- Where
- Berlin, Bottrop, Leipzig, Schwerte
- Age
- 18 years and over
- People
- 25 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00 - Phase 1/2WithdrawnStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Bayern, Berlin, Heidelberg, Mainz
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00